Minerva Neurosciences (NASDAQ:NERV) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report report published on Saturday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright cut their target price on shares of Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th.

Minerva Neurosciences Stock Down 11.5 %

Shares of Minerva Neurosciences stock opened at $2.32 on Friday. Minerva Neurosciences has a fifty-two week low of $2.26 and a fifty-two week high of $13.49. The firm has a market cap of $16.22 million, a price-to-earnings ratio of -0.52 and a beta of 0.18. The business has a fifty day simple moving average of $2.65 and a 200-day simple moving average of $2.80.

Minerva Neurosciences (NASDAQ:NERV) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.12). Analysts anticipate that Minerva Neurosciences will post -2.26 earnings per share for the current fiscal year.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.